Screening and characterization of aptamers for recombinant human programmed death-1 and recombinant extracellular domain of human programmed death ligand-1.
Eur Rev Med Pharmacol Sci
; 25(11): 3997-4004, 2021 06.
Article
em En
| MEDLINE
| ID: mdl-34156677
ABSTRACT
OBJECTIVE:
Programmed death ligand-1 (PD-L1) is expressed on tumor cells and macrophages. The detection of PD-L1 expression in cancer and the treatment by targeting the PD-L1/programmed death-1 (PD-1) are of great clinical significance. This work aims to screen the aptamers with high affinity and specificity for recombinant human PD-1 (rhPD-1)/recombinant human PD-L1 extracellular domain (rhPD-L1). MATERIALS ANDMETHODS:
In this study, we have expressed, purified, prepared, and identified rhPD-1 and rhPD-L1. The rhPD-L1/rhPD-1 aptamers with high afï¬nity and speciï¬city were obtained by systematic evolution of ligands by exponential enrichment technique. Ten aptamers sequences to rhPD-L1 and 10 aptamers sequences to rhPD-1 were obtained by cloning and sequencing. The afï¬nity and speciï¬city of candidate aptamers were analyzed by gold nanoparticles-based colorimetric assay, dot blot assay, and electrophoretic mobility shift assay.RESULTS:
The aptamers named A6 were picked out as the optimal aptamers that recognize PD-1, speciï¬cally with the Kd value of 47.84 ± 24.78 nM. The aptamers named B10 were picked out as the optimal aptamers that recognize PD-L1, speciï¬cally with the Kd value of 59.72 ± 15.87 nM.CONCLUSIONS:
The study lays a foundation for the development of detection methods and therapeutic drugs targeting PD-L1/PD-1.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Aptâmeros de Nucleotídeos
/
Antígeno B7-H1
/
Receptor de Morte Celular Programada 1
Tipo de estudo:
Diagnostic_studies
/
Screening_studies
Limite:
Humans
Idioma:
En
Revista:
Eur Rev Med Pharmacol Sci
Assunto da revista:
FARMACOLOGIA
/
TOXICOLOGIA
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
China